AUG 1 0 2005 EN TRANS

1639

PTO/SB/21 (09-04)

MART	Application Number
TRADENTRANSMITTAL	Filing Date
FORM	First Named Inventor
	A -4 1 - 14

(to be used for all correspondence after initial filing)

 Application Number
 09/526,106

 Filing Date
 March 15, 2000

 First Named Inventor
 Balint, Robert F.

 Art Unit
 1639

 Examiner Name
 Epperson, Jon D.

 Attorney Docket Number
 021167-000700US

Total Number of Pages in T	his Submission 20	Attorney Docket Num	oer 0	21167-00070	00US		
	EN	CLOSURES (Che	ck all that app	oly)			
Extension of Time F Express Abandonm Information Disclose Certified Copy of Pr Document(s) Reply to Missing Pa Application Reply to Mis under 37 CF	eclaration(s) Request Dent Request Ure Statement Rem Rem Rem Rem Rem Rem Rem Re	Account 20-1430. URE OF APPLICANT, ATTORNEY, C		App of A App of A App (Ap) App (Ap) App (Ap) App Other A	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Response to Notice to Comply, Sequence Listing (CRF, paper copy), copy of Notice, return postcard		
Signature	emith E.	nh					
Printed name Kenne	eth E. Jenkins	-					
Date Augus	st 5, 2005		Reg. No.	51,846			
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.							
Signature	Signature Luiotly of Paulen						
Typed or printed name	Timothy S. Parker	, word on the	, c facul		Date	August 5, 2005	



Notice to Comply

Application No. 09/526,106	Applicant(s) Balint et al.	
Examiner Jon D. Epperson	Art Unit 1639	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

\boxtimes	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
\boxtimes	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
\boxtimes	7. Other: Please see attached Raw Sequence Listing Error Report
	plicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
ent	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its ry into the specification, as well as an amendment specifically directing its entry into the ecification.
app	A statement that the content of the paper and computer readable copies are the same and, where blicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 25(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (571) 272-0951

Patentin Software Program Support

To Purchase Patentin Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY